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Chronic	inflammation	increases	cancer	risk.	While	it	is	clear	that	cell	signaling	elicited	by	inflammatory	
cytokines	promotes	tumor	development,	the	impact	of	DNA	damage	production	resulting	from	inflamma-
tion-associated	reactive	oxygen	and	nitrogen	species	(RONS)	on	tumor	development	has	not	been	directly	
tested.	RONS	induce	DNA	damage	that	can	be	recognized	by	alkyladenine	DNA	glycosylase	(Aag)	to	initiate	
base	excision	repair.	Using	a	mouse	model	of	episodic	inflammatory	bowel	disease	by	repeated	administra-
tion	of	dextran	sulfate	sodium	in	the	drinking	water,	we	show	that	Aag-mediated	DNA	repair	prevents	colonic	
epithelial	damage	and	reduces	the	severity	of	dextran	sulfate	sodium–induced	colon	tumorigenesis.	Impor-
tantly,	DNA	base	lesions	expected	to	be	induced	by	RONS	and	recognized	by	Aag	accumulated	to	higher	levels	
in	Aag-deficient	animals	following	stimulation	of	colonic	inflammation.	Finally,	as	a	test	of	the	generality	of	
this	effect	we	show	that	Aag-deficient	animals	display	more	severe	gastric	lesions	that	are	precursors	of	gastric	
cancer	after	chronic	infection	with	Helicobacter pylori.	These	data	demonstrate	that	the	repair	of	DNA	lesions	
formed	by	RONS	during	chronic	inflammation	is	important	for	protection	against	colon	carcinogenesis.
Introduction
Chronic inflammation has emerged as an important risk factor for 
cancer. One of the best examples of the association between chronic 
inflammation and cancer is found in the heightened predisposi-
tion for cancer of patients suffering from ulcerative colitis (UC) and 
Crohn disease of the colon, the major forms of idiopathic inflam-
matory bowel disease. Colorectal cancer (CRC) risk correlates with 
extent and duration of disease (1). Extensive UC leads to a 19-fold 
increase in risk for colon cancer, and about 5% of UC patients devel-
op tumors (2). Cancer risk is likely due to chronic inflammation of 
the gastrointestinal mucosa (3); current UC therapies target inflam-
mation to alleviate symptoms, and approximately 30% of cancer-
free patients have their colons removed to prevent cancer. Another 
major disease linked to chronic inflammation is gastric cancer, the 
second leading cause of cancer death worldwide (4). In this case, the 
predisposing inflammation is most often caused by colonization of 
the gastric epithelium by Helicobacter pylori, and chronically infected 
individuals have an increased risk of developing gastric cancer (5). 
While it is clear that inflammatory cytokines contribute to inflam-
mation-associated cancer susceptibility (6, 7), the possible, and 
likely, contribution of the DNA damage that accompanies chronic 
inflammation has not been tested.
In the 2-stage carcinogenesis model, cancer development begins 
when somatic cells incur irreversible DNA sequence alterations 
(initiation stage). Subsequently, continuous or repeated stimuli 
lead to a sustained induction of cellular proliferation, bringing 
about changes in the cellular microenvironment that favor tumor 
formation (promotion stage). While the cancer initiation stage 
is better defined (e.g., mutation of oncogenes, tumor suppressor 
genes, and other key regulators of cell proliferation), the promo-
tion stage, in which many cell types interact via secreted factors, is 
more complex. Chronic inflammation is an important tumor pro-
moter (6, 8). An acute inflammatory response begins when neutro-
phils infiltrate sites of injury by responding to chemical cues elic-
ited by proinflammatory cytokines and chemokines. Subsequent 
resolution or healing is associated with release of antiinflamma-
tory cytokines. In contrast, chronic inflammation is a response 
to persistent injury and/or infection and involves lymphocytes, 
plasma cells, macrophages, and neutrophils.
In addition to eliciting a variety of cellular signals, inflammation 
generates mutagenic compounds. The reactive oxygen and nitro-
gen species (RONS) produced by neutrophils and macrophages 
(6) can directly induce DNA base oxidation and deamination and 
can indirectly lead to base alkylation via lipid peroxidation (LPO). 
Etheno-modified (ε-modified) bases are generated by reactions of 
DNA with a major LPO product (trans-4-hydroxy-2-nonenal). LPO 
is increased in rectal biopsy samples from patients with active UC, 
consistent with findings regarding RONS-induced lipid damage 
(9). Indeed, increased levels of 1,N6-ethenoadenine (εA), 1,N2-
ethenoguanine (εG), and 3,N4-ethenocytosine (εC) are found in 
the DNA of affected tissues (10). Furthermore, an oxidized base 
lesion, 7,8-dihydro-8-oxoguanine (8oxoG) is found increased in 
the inflamed colonic mucosae of rats and in the inflamed gastric 
mucosae of H. pylori–infected people (11, 12).
All above-mentioned RONS-associated base damage can be 
repaired by the base excision repair (BER) pathway, initiated by 
one of many damage-specific glycosylases that cleave the glyco-
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sylic bond between the damaged base and the sugar phosphate 
backbone (13). A link between BER deficiency and CRC is seen in 
attenuated familial adenomatous polyposis syndrome, in which 
inactivating recessive mutations in the MYH glycosylase (the glyco-
sylase that removes the adenine opposite 8oxoG) sensitize to cancer 
development (reviewed in ref. 14). Myh-deficient mice are more sus-
ceptible to spontaneous tumors either alone (15, 16) or in combina-
tion with 8-oxoguanine DNA glycosylase 1 (Ogg1) deficiency (17). 
Myh-deficient mice were also found to be susceptible to oxidative 
stress–induced intestinal tumors (15). Additionally, Ogg1 knockout 
mice were reported to be more susceptible to spontaneous lung 
tumorigenesis (18). Most importantly however, the role of inflam-
mation in affecting tumor susceptibility in mice deficient in any of 
the above-mentioned glycosylases has not yet been investigated.
Alkyladenine DNA glycosylase (Aag) has a broad substrate speci-
ficity (13). Base lesions formed by RONS that can be removed by 
Aag include hypoxanthine (Hx) (caused by deamination of ade-
nine), εA, and εG. Furthermore, the major oxidized base lesion 
8oxoG can be removed by Aag, albeit inefficiently, and the mouse 
enzyme has greater activity than the human enzyme toward this 
adduct (19). Not only does Aag excise DNA base lesions induced 
by RONS, AAG levels increase in inflamed regions of the colon 
epithelium in UC patients, suggesting that AAG expression adapts 
in response to increased DNA damage in inflamed tissues (20).
Here we tested whether RONS-induced DNA damage contrib-
utes to tumor development in a common mouse model of chronic 
inflammation. We stimulated episodic colitis in WT and Aag–/– 
mice by administering repeated cycles of dextran sulfate sodium 
(DSS) to induce chronic colonic inflammation that is morpholog-
ically similar to human UC (21, 22). DSS does not directly damage 
DNA. However, repeated DSS cycles mimic episodic inflammation 
in UC and induce colon adenomas and adenocarcinomas in WT 
mice in a variety of strain backgrounds (21, 23). Our results dem-
onstrate that, in mice, Aag is an important suppressor of colon 
cancer in response to chronic inflammation, thus providing robust 
evidence that repair of RONS-associated DNA lesions is important 
for the suppression of inflammation-induced tumorigenesis. As a 
test of the generality of this effect, we also demonstrate that Aag 
Figure 1
Increased tumor multiplicity in Aag–/– versus Aag+/+ animals treated with AOM and DSS. (A) Treatment scheme. White blocks represent 16 days of 
normal water except the last which is 7 days. Black blocks represent 5 days of 2.5% DSS in water except for the last, which was 4 days of 2% DSS. 
Mice were also treated with only AOM or only DSS. (B) Tumor multiplicity in Aag+/+ animals (white), and Aag–/– animals (black). AOM+DSS Aag+/+, 
n = 12; AOM+DSS Aag–/–, n = 23; AOM Aag+/+, n = 15; AOM Aag–/–, n = 19; DSS Aag+/+, n = 10; and DSS Aag–/–, n = 10. Data are mean ± SD. (C) 
Pathology scores for Aag+/+ (circles) and Aag–/– (diamonds) mice. See Supplemental Methods for a complete description of scoring criteria. Lines 
indicate the median. (D) Photomicrographs depicting, from left to right, normal untreated Aag+/+ colon; AOM+DSS-treated Aag+/+ colon bearing a 
lesion with an average dysplasia score, a sessile adenoma; normal untreated Aag–/– colon; and AOM+DSS-treated Aag–/– colon bearing a lesion 
with an average dysplasia score and a higher scoring pedunculated adenoma. Scale bars: 200 μm.
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attenuates the development of gastric cancer precursors induced 
by H. pylori infection.
Results
Tumorigenesis induced by azoxymethane initiation and DSS promotion. It 
has been proposed that chronic inflammation enhances tumori-
genesis via the induction of DNA damage by RONS (24). To test 
this hypothesis, we examined whether Aag-dependent DNA repair 
influences chronic inflammation–dependent tumorigenesis. We 
induced chronic colonic inflammation in Aag+/+ and Aag–/– mice 
by feeding repeated cycles of DSS. DSS cycles were preceded (or 
not) by a single injection of the colonic carcinogen azoxymeth-
ane (AOM). C57BL/6J mice are relatively refractory to spontane-
ous tumors of epithelial origin (25), and it was previously shown 
that a 70%–90% colon tumor incidence in C57BL/6J mice requires 
12 cycles of DSS (23). We therefore chose a colon carcinogenesis 
protocol wherein an initial exposure to AOM is followed by fewer 
cycles of DSS (modified from refs. 1, 7). The treatment scheme is 
illustrated in Figure 1A.
Figure 1B shows the analysis of tumor multiplicity in Aag+/+ and 
Aag–/– animals treated with AOM and DSS, either alone or in com-
bination. For AOM+DSS there was a 3.0-fold increase (P < 0.0001) 
in tumor multiplicity in Aag–/– animals with 22 ± 8.2 tumors 
per mouse; Aag+/+ animals had only 7.7 ± 6.7 tumors per mouse. 
AOM+DSS-treated Aag–/– animals also scored higher for severity of 
dysplasia and for the magnitude of the area affected (Figure 1C). 
All tumors were located in the mid- to distal colon, and included 
sessile and pedunculated adenomas with high-grade dysplasia and 
a moderate inflammatory component but no invasion of the 
muscularis mucosae (Figure 1D).
Treatment with a single dose of AOM did not lead to tumor 
development in either Aag–/– or Aag+/+ mice (Figure 1B). 
Treatment with 5 cycles of DSS alone led to a similar result 
for Aag–/– and Aag+/+ animals in terms of tumor multiplic-
ity. For Aag–/– animals, the multiplicity was 0.3 ± 0.8 tumors 
per mouse (3 tumors in 10 animals), and for Aag+/+ animals, 
0.2 ± 0.6 tumors per mouse (2 tumors in 10 animals). 
Although there were no significant differences in tumor 
multiplicity or incidence between Aag+/+ and Aag–/– mice 
treated with 5 cycles of DSS, it was clear that there were 
major pathological differences between Aag+/+ and Aag–/–ani-
mals, as shown in Figure 1D and in Figure 2 (see below).
  DSS-induced general pathologies are more severe in Aag–/– mice. 
We assessed the following colitis-related disease markers: 
decreased colon length due to healing ulcers and fistulas (Figure 
2A) and increased spleen weight (Figure 2B). As shown in Figure 
2A, colons from Aag–/– mice were significantly shorter than those 
of Aag+/+ mice treated with AOM+DSS or treated with DSS alone. 
Changes in spleen weight also indicate that DSS-induced colitis 
affects Aag–/– more severely than Aag+/+ mice. Colitis-associated sple-
nomegaly, as determined by spleen weight and histopathology, was 
attributable to extramedullary hematopoiesis, presumably to replen-
ish blood lost through stools due to tumors or ulcerations and to 
supply neutrophils to inflamed areas. Figure 2B shows a significantly 
greater increase in spleen weight in Aag–/– versus Aag+/+ animals for all 
treatment groups (P < 0.01). Note that the Aag+/+ spleen weight only 
increased when DSS treatment was preceded by AOM treatment, yet 
DSS treatment alone led to a significant increase in the Aag–/– spleen 
weight compared with untreated Aag–/– animals (P = 0.002) and com-
pared to similarly treated Aag+/+ animals (P = 0.002). Taken together, 
these results show that Aag–/– animals respond more profoundly to, 
and manifest slower recovery from, DSS-induced chronic inflamma-
tion compared with Aag+/+ animals.
Intestinal changes at the cellular level were determined by his-
topathological analysis. H&E-stained colon sections were scored 
blindly for inflammation, epithelial defects, and crypt atrophy. 
Scoring criteria are described briefly in Methods and in full in 
Supplemental Methods (supplemental material available online 
with this article; doi:10.1172/JCI35073DS1). Five cycles of DSS 
induced similar levels of inflammation in Aag+/+ and Aag–/– animals, 
as judged histologically by the degree of leukocyte infiltration, 
aggregation, and follicle formation (see Supplemental Methods for 
Figure 2
Aag–/– animals are more susceptible than Aag+/+ animals to 
DSS-induced colitis. (A) Change in colon length. (B) Spleen 
weight as a percentage of body weight. AOM+DSS Aag+/+, 
n = 14; AOM+DSS Aag–/–, n = 31; AOM Aag+/+, n = 15; AOM 
Aag–/–, n = 19; DSS Aag+/+, n = 10; DSS Aag–/–, n = 10. Data are 
mean ± SD. (C) Histopathology scores for severity of inflamma-
tion, epithelial defects, and crypt atrophy. A description of the 
histopathological endpoints for inflammation examined can be 
found in Supplemental Methods. Epithelial defect scores were 
based on increased gland dilation and surface epithelial attenu-
ation. (D) Photomicrographs showing a DSS-treated Aag+/+ 
colon bearing a lesion with an average epithelial defect score 
(left) and a DSS-treated Aag–/– colon bearing a lesion with an 
average epithelial defect score (right). Scale bars: 100 μm.
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description of scoring criteria). However, significant differences in 
epithelial defects were seen for Aag–/– versus Aag+/+ mice (Figure 2, C 
and D). Even though there is no histological difference in the level 
of chronic inflammation, the cellular and tissue defects are more 
severe in Aag–/– animals. These results prompted us to evaluate the 
effects of longer DSS administration in the Aag mutant model.
Aag deficiency enhances tumor development with extensive cycles of DSS. 
Given 7 cycles of DSS in drinking water (Figure 3A), Aag–/– animals 
developed more tumors than Aag+/+ mice and were much more 
severely affected for most pathophysiological criteria measured. 
With regard to tumor development, 7 of the 18 Aag–/– animals 
(39%) developed tumors, while none of the similarly treated WT 
mice (n = 7) developed any tumors (P = 0.07). All 7 affected Aag–/– 
animals had 1 colonic polyp displaying significant dysplasia (score 
of 2.5–3; Figure 3D).
Colon lengths decreased and spleen weights increased more in 
Aag–/– versus Aag+/+ animals (Figure 3, B and C). Moreover, histo-
pathological scores for inflammation, epithelial defects, and crypt 
atrophy were significantly higher in the Aag–/– cohort versus the 
Aag+/+ mice (Figure 3D). While the extent and severity of dysplasia 
were generally worse in Aag–/– versus Aag+/+ mice, the differences in 
their histopathological scores did not reach significance (Figure 
3D). Figure 3E shows examples of the severity of colonic disease 
induced by 7 cycles of DSS in Aag+/+ and Aag–/– animals. Lesions in 
Aag+/+ mice included moderate mucosal and submucosal inflamma-
tion plus glandular epithelial hyperplasia (Figure 3E, WT untreated) 
and moderate dysplasia (Figure 3E, WT+DSS), whereas lesions in 
Aag–/– mice were worse, with moderate to severe mucosal and sub-
mucosal inflammation, crypt atrophy, and mucosal collapse (Figure 
3E, Aag–/– untreated) and with highly dysplastic adenomas also pres-
ent in some animals (Figure 3E, Aag–/–+DSS). Taken together, these 
data show that even in the absence of an initiating dose of AOM, 
Aag–/– animals are more susceptible than Aag+/+ to the detrimental 
effects of chronic inflammation induced by repeated DSS cycles.
Aag suppresses the severity of gastric lesions following infection with H. pylori. 
To determine whether Aag influences disease progression in another 
model of chronic inflammation, we infected Aag+/+ and Aag–/– mice 
with the pathogen H. pylori and analyzed gastric pathology at 32 
weeks after infection. Although no gastric cancer developed dur-
ing this relatively short experimental time frame, Aag–/– mice were 
Figure 3
Increased severity of disease in Aag–/– versus Aag+/+ animals treated with 7 cycles of DSS. (A) Treatment scheme. (B) Decrease in colon length 
for Aag–/– animals (n = 18) compared with Aag+/+ animals (n = 7). (C) Increase in spleen weight as a percentage of body weight for Aag+/+ (n = 7) 
and Aag–/– animals (n = 18). Data are mean ± SD. (D) Pathology scores for Aag+/+ (circles) and Aag–/– (diamonds) mice. (E) Histopathology of 
colonic disease induced by 7 cycles of DSS. From left to right: Aag+/+ colon exhibited moderate inflammation and glandular epithelial hyperpla-
sia; Aag+/+ colon exhibited mild dysplasia characterized by epithelial cell pleomorphism and mild branching, with hyperplasia and inflammation; 
Aag–/– colon exhibited moderate to severe inflammation, crypt atrophy, mucosal collapse, and segmental epithelial cell loss; Aag–/– colon exhib-
ited a portion of an intraepithelial neoplasia with mucosal dysplasia characterized by loss of columnar orientation, elongation, branching and 
infolding, glandular ectasia, inflammation, and crypt abscesses. Scale bars: 100 μm.
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clearly more susceptible to developing histopathologic lesions 
that were markers of increased predisposition to, or were precur-
sors to, gastric cancer (26–28) (Figure 4A). Aag–/– mice had sig-
nificantly more oxyntic atrophy (P = 0.002), foveolar hyperplasia 
(P = 0.04), and mucosal metaplasia (P < 0.001) (Figure 4B). Impor-
tantly, the innate and adaptive immune responses to the bacteria 
were unaffected by the Aag genotype: Aag–/– and Aag+/+ mice had 
similar histopathological scores for inflammation and serum lev-
els of the H. pylori–specific IgG1 and IgG2c antibodies (Figure 4C). 
Also, the colonization of the gastric mucosa by H. pylori, as mea-
sured by quantitative PCR, was unaffected by Aag genotype (Figure 
4D). In summary, the inflammatory response to H. pylori in Aag+/+ 
and Aag–/– mice is the same, but Aag–/– mice develop significantly 
more severe gastric lesions that are precursors to gastric cancer.
Aag does not suppress tumorigenesis in the absence of chronic inflam-
mation. It was possible that Aag might influence tumor develop-
ment independent of chronic inflammation. However, this did 
not appear to be the case. When crossed with ApcMin mice, a robust 
genetic model for identifying modifiers of intestinal tumorigenesis 
that does not involve chronic inflammation, Aag+/+ and Aag–/– mice 
had nearly identical tumor responses (Supplemental Figure 1). Aag 
did not affect tumor multiplicity in either the small intestine (Sup-
Figure 4
Increased severity of stomach pathology in Aag–/– 
versus Aag+/+ animals infected with H. pylori. (A) His-
topathology of gastric disease and mucosal meta-
plasia induced by H. pylori infection in the stomach 
mucosa of Aag+/+ or Aag–/– mice. Uninfected Aag+/+ 
mouse stomach showed normal microscopic archi-
tecture (H&E) and a thin surface lining of gastric-
type neutral mucins (red; AB/PAS), and anti-TFF2 
stained intermittent mucous neck cells within normal 
oxyntic mucosa. Uninfected Aag–/– mice were indis-
tinguishable from the uninfected Aag+/+, so only the 
Aag+/+ is shown. For infected Aag–/– mice, moderate 
gastritis with marked mucous metaplasia, hyperpla-
sia, and oxyntic atrophy (loss of parietal and chief 
cells) was observed (H&E). Hyperplastic mucous 
neck cell population replaced resident zymogenic 
cells, secreting a mixture of gastric (red) and intes-
tinal-type (acidic, blue) mucins (AB/PAS). Mucous 
metaplasia associated with expanded mucous neck 
cell population highlighted by TFF2 immunoreactiv-
ity. For infected Aag+/+ mice, gastritis but minimal 
oxyntic alterations were observed (H&E). Mucous 
neck cells were significantly reduced in number 
in the Aag+/+ H. pylori–infected mouse (AB/PAS). 
Fewer TFF2-positive mucous neck cells were 
observed in the infected Aag+/+ mouse. Scale bars: 
160 μm. (B) Pathology scores for infected Aag+/+ 
(circles) and infected Aag–/– (diamonds) mice. (C) 
Serum IgG1 and IgG2c responses to H. pylori in 
Aag–/– and Aag+/+ mice 32 weeks after infection. (D) 
H. pylori colonization levels in the stomach. Data 
presented as mean ± SD of log-transformed CFU/μg 
of genomic DNA.
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plemental Figure 1A) or the colon (Supplemental Figure 1B) or the 
distribution of tumors throughout the entire intestine (Supple-
mental Figure 1C). Furthermore, tumor size was unaffected by Aag 
(Supplemental Figure 1D). In summary, in the absence of inflam-
mation, we observed no effect of Aag on colon tumorigenesis.
It was also possible that Aag–/– mice were differentially sensitive 
to the single dose of AOM used to initiate tumorigenesis. C57BL/6J 
animals form appreciable numbers of aberrant crypt foci (ACF) in 
response to AOM (29), but in the absence of treatment with exog-
enous tumor promoters, neoplasia is infrequent. To determine 
whether Aag modulates this initiation response, colons from ani-
mals treated with AOM alone were examined for ACF formation. 
Aag deficiency had no effect on ACF formation (Supplemental 
Figure 2). Similarly, Aag deficiency had no significant effect on 
tumor responses following 5 weekly treatments with AOM, as 2 
of 8 Aag+/+ animals and 1 of 12 Aag–/– animals each developed a 
single tumor. This result is consistent with the low overall tumor 
response of C57BL/6J animals to AOM in the absence of subse-
quent chronic inflammation. This confirms that the heightened 
susceptibility of Aag–/– mice to tumor formation in the 2-stage car-
cinogenesis model is not due to a differential response to the ini-
tiating carcinogen, AOM, but rather to the chronic inflammation 
induced by DSS exposure.
Finally, it was possible that Aag–/– animals respond aberrantly to 
episodic bouts of colitis because of an altered innate inflammatory 
response. To address this issue, we used Citrobacter rodentium to 
evaluate the effects of acute inflammation in Aag–/– versus Aag+/+ 
animals; such infection induces acute hyperplastic colitis (30). No 
Figure 5
Induction of εA, εC, and 8oxoG lesions by chronic inflammation and Ctnnb1 mutations in colon tumors. Six- to 8-week-old male mice were 
untreated or were administered 2.5% DSS for 5 days and euthanized 1 or 7 days after treatment. Levels of the modified bases εA (A), εC (B), and 
8oxoG (C) were measured from colonic mucosal DNA and are shown for Aag-proficient (+) and Aag-deficient (–) mice. Within treatment groups, 
we observed no differences between Aag+/+ and Aag–/– mice, and thus these genotypes were combined in the analysis. Data are mean ± SD. 
(D–F) Point mutations in Ctnnb1. (D and E) Chromatogram showing an example of the most common mutation observed, a G:C to A:T transition 
in codon 41 of Ctnnb1. The arrow indicates the peaks for the mutant and WT sequences. (E and F) Distribution of mutations in Ctnnb1. Base sub-
stitutions are indicated below the sequence, and their frequencies are shown for the different experimental groups. (F) Deletion mutants in Ctnnb1. 
Chromatograms of the 2 deletion mutants are shown with an arrow below the sequence indicating the deletion junction. Also shown is the deleted 
sequence (lowercase) with red highlighting of regions of microhomology between the deleted portion and the adjacent retained sequence.
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clinical disease was observed in Aag+/+ or Aag–/– mice infected with 
C. rodentium (data not shown). Fecal bacterial shedding was detect-
ed at 4 days after infection and was indistinguishable between 
Aag+/+ and Aag–/– mice throughout 30 days of the experiment (Sup-
plemental Figure 3). Similarly, there were no differences between 
Aag+/+ and Aag–/– mice with regard to colonic lesions throughout 
the course of the infection, and these lesions were largely resolved 
by 30 days after infection. Thus, we observed no effect of Aag on 
mounting an acute inflammatory reaction.
Modified bases following DSS treatment. Given the results presented 
above, our working hypothesis was that DSS-induced colitis 
results in RONS-induced DNA damage that is poorly repaired in 
the absence of Aag and that the unrepaired DNA lesions enhance 
tumorigenesis. In support of this hypothesis, we demonstrated that 
reactive nitrogen species are indeed formed after DSS treatment, by 
positive staining for nitrotyrosine, a known marker for NO-induced 
peroxynitrite formation, in colons of both WT and Aag–/– mice 
treated with AOM+DSS (Supplemental Figure 4). In addition, we 
used a recently developed and extremely sensitive LC/MS method to 
measure endogenous levels of a selection of DNA lesions known to 
be induced by RONS (31). We quantified the modified DNA bases 
εA, εC, 8oxoG, and Hx in colonic epithelial DNA from untreated 
and DSS-treated mice. Levels for all modified bases in the untreated 
groups were not appreciably different between Aag-proficient and 
Aag-deficient animals, suggesting that Aag does not affect the 
accumulation of these lesions in the colons of relatively young 
animals that have not experienced colitis (Figure 5). After a single 
cycle of DSS, levels of εA and εC increased significantly relative to 
the untreated groups (P < 0.0002) and increased with time in both 
groups of animals after DSS was terminated (P < 0.04) (Figure 5, 
A and B). These increases were more dramatic in the Aag-deficient 
versus Aag-proficient animals. At 1 and 7 days after treatment, the 
εA increase was 1.5- and 1.8-fold higher in Aag-deficient than that in 
Aag-proficient animals, respectively (Figure 5A), and εC was 1.4- and 
2.0-fold higher (Figure 5B), respectively. These differences represent 
significant effects of Aag on the levels of both ε-lesions in response 
to DSS (P = 0.01 for both) treatment. Levels of εA in the Aag-defi-
cient mice showed the greatest difference of any lesion relative to 
untreated mice. Seven days after DSS treatment was terminated, 
Aag-deficient mice had 14-fold higher levels of εA compared with 
the mean levels from all untreated mice.
Levels of 8oxoG also increased with DSS treatment (P = 0.05) and, 
like εA and εC, it increased to higher levels in Aag-deficient versus 
Aag-proficient animals. At 1 and 7 days after DSS was stopped, 
the increases in 8oxoG levels were 1.7- and 1.8-fold higher in Aag-
deficient mice versus those in Aag-proficient mice (P = 0.01) (Fig-
ure 5C). Although there was a trend for increasing levels of Hx in 
the colonic mucosae of repair deficient mice, the overall effect of 
inflammation on levels of this lesion were not significant (P = 0.2) 
(Supplemental Figure 5).
Oncogenic mutations. Microdissected tumors were analyzed to 
determine whether damage that resulted from RONS affected the 
mutation spectra in the candidate oncogenes Ctnnb1 and Kras2, 
which are commonly mutated in mouse colon tumors (Figure 5 
and Supplemental Table 1). We sequenced a portion of exon 2 from 
Ctnnb1 (homologous to exon 3 in human CTNNB1) correspond-
ing to the coding sequence for the glycogen synthase kinase-3β 
phosphorylation domain. In addition, we sequenced portions of 
exons 1 and 2 from Kras2, corresponding to the coding sequences 
for the codon 12 and codon 61 regions, respectively. Oncogenic 
mutations were detected in Ctnnb1 in most tumors analyzed, while 
only 1 tumor among all groups had a mutation in Kras2 (a G:C 
to A:T transition in the second base of codon 13 from a tumor in 
an Aag–/– mouse treated with AOM+DSS) (Supplemental Table 1). 
Figure 5E shows an example of the most common mutation, 
observed at codon 41 in Ctnnb1, and Figure 5F shows the posi-
tions for all identified base substitutions. When tumors were initi-
ated with AOM, all but 1 of the mutations were G:C to A:T tran-
sitions, reflecting the mutational specificity of this carcinogen. 
Aag–/– animals that were treated with DSS alone showed a similar 
fraction of tumors with mutations in Ctnnb1 (5 of 6). However, in 
this group only 2 of the 5 mutations were G:C to A:T transitions, 
while the others included an A:T to G:C transition and 2 in-frame 
deletion mutations (Supplemental Table 1 and Figure 5F). While 
the sample size is small, the fraction of deletion mutants (2 of 5) 
represents a significant difference (P = 0.02) from that of the com-
bined tumors from Aag–/– and Aag+/+ mice treated with AOM+DSS 
(0 of 26). These results suggest that oncogenic deletion mutants 
are generated by unrepaired RONS-induced lesions in DNA.
Discussion
Every year, approximately 1 million cases of CRC are diagnosed 
worldwide. Those with a familial component could constitute 10% 
to 50% of all CRC cases (4, 32), but the fraction of cases caused 
by highly penetrant familial cancer syndromes such as Lynch 
syndrome or familial adenomatous polyposis is relatively small. 
Indeed, the genetic basis for most cases of familial susceptibility is 
unknown (32). It is likely that a combination of low and moderately 
penetrant genes interact with environmental factors to modify 
risk for CRC (33). Approximately 5% of patients with UC develop 
colon cancer, and no susceptibility genes for inflammation associ-
ated CRC have been identified (2). Being able to identify those in 
the population who are at increased risk of CRC could reduce the 
number of CRC-related deaths.
We report here that Aag deficiency in a mouse model grossly 
increases the extent of pathology in the intestinal mucosa in 
response to chronic inflammation. This deficiency enhances 
inflammation-associated colon tumorigenesis in 2 carcinogen-
esis protocols, treatment with AOM+DSS and treatment with 
DSS alone. As a measure of the generality of this effect, following 
infection with H. pylori, Aag deficiency predisposes to the develop-
ment of gastric cancer precursor lesions. H. pylori chronic gastri-
tis is associated with increased production of RONS in the host 
(reviewed in ref. 34). This pathogen is an enormous public health 
concern, with over 50% of the world population being infected and 
5% of all human cancers attributed to H. pylori infection and its 
associated inflammation (35, 36). Finally, Aag had no effect on 
the development of AOM-induced ACF or tumor development 
and had no effect on spontaneous tumorigenesis in mice on the 
ApcMin background, indicating that Aag suppresses chronic inflam-
mation-related cancer development.
The number of ε-base lesions and 8oxoG increased in the colons 
of mice after a single DSS cycle, consistent with previous reports 
that inflammation is associated with increased ε-base lesions (10, 
37), that ε-base lesions increase more than oxidized or deaminat-
ed lesions in response to inflammation (31), and that 8oxoG is 
induced by DSS treatment in rats (12). Moreover, inflammation-
induced εA, εC, and 8oxoG increased more dramatically in the 
Aag-deficient animals, consistent with the ability of Aag to excise 
both εA and 8oxoG. Interestingly, although Aag binds tightly to 
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εC, it does so without catalyzing its excision (38); it seems likely 
that the binding of Aag to εC in vivo facilitates its repair via an 
alternative repair pathway. In summary, the accumulation of DNA 
base damage in Aag–/– mice in response to DSS provides a causal 
link between repair deficiency and carcinogenesis. Our data dem-
onstrate that DNA repair under chronic inflammatory conditions 
is an important suppressor of cancer development.
Chronic inflammation produces a complex milieu of growth fac-
tors and cytokines that cause general hyperplasia, and we propose 
that the proliferative and antiapoptotic signals generated during 
chronic inflammation act synergistically with DNA damage to 
enhance cancer development (6–8). Our results are consistent with 
2 different but not mutually exclusive effects of RONS-dependent 
DNA damage that could lead to increased tumor development in 
a repair-deficient situation (Figure 6). One effect involves a snow-
balling mechanism of increased levels of cellular damage and 
death leading to more inflammation, which in turn produces more 
tumor-promoting cytokines and more RONS (Figure 6). Consis-
tent with this model is our observation that Aag–/– mice had much 
more severe gross pathological and general histopathological 
changes than Aag+/+ with DSS treatment. The differences between 
Aag–/– and Aag+/+ mice were evident at 5 cycles but were much more 
dramatic at 7 cycles. Importantly, after 7 cycles of DSS Aag–/– mice 
had significantly more general inflammation than Aag+/+ mice.
Another effect that is likely acting in concert with that described 
above is that base damage in the presence of proliferative and anti-
apoptotic signals could serve to fix and expand cancer-causing 
mutations (Figure 6). Of the base lesions found at higher levels 
with DSS treatment and Aag deficiency, εA induces A:T to G:C 
and A:T to T:A mutations, εC induces C:G to A:T and C:G to T:A 
mutations, and 8oxoG induces G:C to T:A transversions (39–41). 
In addition, both εC and εA are replication-blocking lesions (38, 
42). It has been reported that DSS promotion of AOM- or dimeth-
ylhydrazine-initiated tumors (AOM is a proximal carcinogen of 
dimethylhydrazine) results in tumors with predominantly G:C to 
A:T transitions in Ctnnb1, consistent with the mutational specific-
ity of these carcinogens (43, 44). However, Greten et al. (7) showed 
that only 3 of 7 tumors from AOM+DSS-treated mice had G:C to 
A:T transitions, while the rest were mutations at A:T base pairs. In 
the present study, tumors from AOM+DSS-treated mice harbored 
predominantly G:C to A:T transitions, and the spectrum was not 
affected by Aag deficiency. In contrast, the pattern was significantly 
different in Aag–/– mice treated only with DSS, in which nearly half 
the mutations in Ctnnb1 were deletions. Such alterations could 
arise from replication-blocking ε-base lesions.
Unlike DSS-induced colon tumors in mice, human UC-associ-
ated cancers commonly harbor TP53 mutations (45, 46). Circum-
stantial evidence that these mutations are caused by RONS lies 
in the fact that RONS enhance deamination at 5MeC, and most 
of the TP53 mutations in UC-associated cancers were G:C to A:T 
transitions at 2 hot-spot CpG dinucleotide sites. Interestingly, 
these mutations are found in both neoplastic and non-neoplastic 
tissue in the UC colon (45, 46).
A panoply of DNA glycosylases have evolved to repair oxidized 
bases in DNA. Among them, OGG1, which removes 8oxoG, and 
MYH, which removes adenine paired with 8oxoG, are important in 
suppressing G:C to T:A transversions and in preventing CRC in peo-
ple and mice (reviewed in ref. 41). These glycosylases suppress CRC 
in the absence of chronic inflammation, and their association with 
inflammation-associated cancer is not known. One might expect 
Ogg1- or Myh-deficient mice to display marked increases in suscep-
tibility to cancer development that is stimulated by inflammation.
In light of our results, AAG and other BER genes are strong candi-
dates for genetic association studies of human CRC or gastric cancer 
risk. Although there are no known polymorphisms that alter AAG 
function, a 20-fold range in activity was observed in peripheral mono-
nuclear cells from over 50 healthy adults (E. Moy, D. Christiani, and 
L.D. Samson, unpublished observations). Indeed, decreased 8oxoG 
DNA glycosylase activity in human blood samples has been associ-
ated with increased lung cancer risk, which may also have an inflam-
matory component (47). Measurements of interindividual differ-
ences in the activity of AAG, OGG, and other DNA glycosylases may 
provide an informative parameter in the multifactorial dissection 
of cancer risk. This may be particularly important for gene-environ-
ment interactions with states of chronic inflammation or with other 
conditions known to increase oxidative stress such as metal storage 
diseases, heavy metal exposure, smoking, and chronic infection.
Methods
Animals
The Aag–/– mouse has been described (48, 49), and Aag–/– animals were back-
crossed into C57BL/6J background for over 12 generations. C57BL/6J-ApcMin 
mice were obtained from The Jackson Laboratory. For the H. pylori studies, 
animals were maintained in microisolator cages as previously described 
(50), and dirty bedding from Aag–/– and Aag+/+ mice were mixed to ensure all 
groups had similar commensal microbial flora. All mice were fed a standard 
diet ad libitum and housed in an AAALAC-accredited facility. Euthanasia 
was by CO2 asphyxiation, and all procedures were approved by the Massa-
chusetts Institute of Technology Committee on Animal Care.
Figure 6
Model for inflammation-induced tumorigenesis. Inflammatory cells 
produce cytokines that induce proliferation and suppress apoptosis. 
The toxic effects of RONS can partially counterbalance these signals, 
leading to cell death or an inability to repopulate eroded regions. Either 
cytotoxicity or cytostasis would require neighboring cells to replicate for 
healing to occur, and under chronic conditions, cell death could further 
stimulate inflammation. In addition, survival factors act in concert with 
RONS-induced miscoding or replication blocking DNA lesions to fix 
and expand cancer-causing mutations.
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Experimental treatments
Colitis-inducing protocol. Colitis was induced by repeated administration of 
DSS for either 5 or 7 cycles beginning at 6–8 weeks of age. Tap water was 
replaced with 2.5% DSS (molecular weight, 36,000–50,000; MP Biomedicals 
Inc.) in distilled water for 5 days followed by 16 days of tap water (except 
for the 5th or 7th cycle, in which 2% DSS was given for 4 days followed by 
5 days of tap water). Five days prior to the first DSS cycle, animals were 
treated (or not) with an initiating i.p. dose of 12.5 mg/kg AOM (Midwest 
Research Institute, NCI Chemical Repository), then subjected to 5 DSS 
cycles. Experiments involving 5 cycles of DSS administration terminated 
on day 100; experiments involving 7 cycles of DSS administration were 
terminated on day 142. Alternatively, animals were treated only with AOM 
(12.5 mg/kg) and euthanized 100 days later, or treated once a week with 
AOM (10 mg/kg) and euthanized 175 days later.
H. pylori study. H. pylori Sydney strain (SS1) was used for oral inoculation 
as described previously (50, 51). The H. pylori concentrations were adjusted 
to OD600 = 1.000 in PBS, and mice were dosed with a 0.2-ml suspension 
by gavage every other day for 3 doses. Control mice were dosed with PBS. 
Animals were euthanized 32 weeks after inoculation.
ApcMin study. ApcMin/+ mice were crossed with Aag–/– mice, and F2 or F3 gen-
eration littermates were used in tumor studies. Animals were euthanized at 
130 days of age and the colon and small intestines were removed, washed 
with PBS, cut open, and measured. Tumors greater than 0.5 mm in diam-
eter were counted under a stereoscope and measured with an ocular reticle. 
The position of each tumor along the length of the intestine was recorded. 
Most tumors that develop in ApcMin mice occur in the small intestine, with 
relatively few in the colon (52).
Histopathology
Colitis experiment. The entire colon from cecum to anus was removed, washed 
with PBS, cut open, and measured. Spleens were weighed and fixed in 10% 
neutral buffered formalin. Polyps were counted using a stereomicroscope 
(magnification, ×45). Proximal and distal colons were fixed in 10% neutral 
buffered formalin for 4 hours, embedded in paraffin, sectioned at 5 μm, 
and stained with H&E for histopathological confirmation of polyps and/
or adenomas (neoplasia). Lesion scores were assigned for inflammation, 
epithelial defects, crypt atrophy, dysplasia/neoplasia, and area affected 
by dysplasia. Inflammation was defined as mild to severe, depending on 
the degree of leukocyte infiltration and extent of inflammation in the 
different cell layers of the colon (mucosa, submucosa, and deeper layers). 
Epithelial defects were scored according to extent and severity of damage 
to the epithelial cell layer. Crypt atrophy was scored by a visual estimate of 
percent atrophy in the colonic crypts in the most affected area. Dysplasia/
neoplasia scores represent the severity of the cellular changes brought on 
by treatment, from mild atypia to severe dysplastic/neoplastic changes. For 
a more detailed description of scoring criteria, see Supplemental Methods. 
Alternatively, colons from animals belonging to the AOM treatment group 
were stained briefly with methylene blue (1%) and rinsed in PBS for scoring 
of ACF. ACF were scored under a stereomicroscope (magnification, ×45). 
No gender differences were observed (data not shown), thus the results for 
female and male mice were combined.
H. pylori study. At necropsy, the stomach and proximal duodenum were 
removed and cut along the greater curvature. Linear gastric strips from the 
lesser curvature were fixed overnight in 10% neutral-buffered formalin or 
70% ethanol, embedded, cut at 4 μm, and stained with H&E. Stomachs from 
infected and control mice were characterized with Alcian blue at pH 2.5 (for 
acidic, intestinal-type mucins) and with periodic acid–Schiff (for neutral, 
gastric-type mucins) (53). Expression of trefoil factor 2 (TFF2) protein was 
characterized by immunohistochemistry (54). Lesions were scored by a vet-
erinary pathologist blinded to sample identity as described previously (53). 
Gastric colonization by H. pylori was quantified using a fluorogenic quanti-
tative PCR assay as previously described (51). Also, serum collected at nec-
ropsy was evaluated for H. pylori–specific IgG1 (Th2-associated isotype) and 
IgG2c (Th1-associated isotype) by ELISA using an outer membrane protein 
preparation from H. pylori (SS1 strain) as previously described (55).
Mutations in oncogenes
Tumors were microdissected using an Arcturus-Veritas 2006 Laser Cap-
ture Microscope, and DNA was prepared for PCR amplification using the 
PicoPure DNA extraction kit (Arcturus). Ctnnb1 exon 2 was amplified with 
primers 5′-GCTGACCTGATGGAGTTGGA-3′ and 5′-GCTACTTGCTCTT-
GCGTGAA-3′. Kras2 exon 1 was amplified with primers 5′ TAAACTTGTG-
GTGGTTGGAGC-3′ and 5′-AGCGTTACCTCTATCGTAGG-3′, and exon 
2 with primers 5′-CTCTTGGATATTCTCGACACAGC-3′ and 5′-TTATG-
GCAAATACACAAAGAAAGC 3′. The Ctnnb1 fragment was sequenced with 
the primer 5′-GCTCTTGCGTGAAGGACTG-3′, Kras2 exon 1 region with 
the reverse primer listed above, and Kras2 exon 2 region with the primer 
5′-ATACACAAAGAAAGCCCTCC-3′. Mutations were scored by visual 
assessment of chromatograms using Sequencher software (Gene Codes 
Corp.). Amplification reactions containing deletion mutants were 
cloned into a blunted HindIII site of pUC18, and at least 2 clones of 
each of the shortened fragments were sequenced with the pUC18 primer 
5′-CCATTCAGGCTGCGCAACTG-3′.
Measurement of modified bases
Six- to 8 week-old male mice were administered 2.5% DSS for 5 days and 
were euthanized 1 or 7 days following treatment. Colons were flushed 
with cold PBS, splayed open, and washed again. The mucosal surface was 
scraped thoroughly with a razor blade in cold PBS. The suspension of 
mucosal cells was transferred to a 15-ml conical tube and harvested by 
centrifugation for genomic DNA isolation (Roche). Antioxidants or deam-
inase inhibitors were added to the PBS, lysis buffer, and protein precipi-
tation solution; coformycin (5 μg/ml), desferrioxamine (0.6 μg/ml), and 
butylated hydroxytoluene (100 μM). εA, εC, 8oxoG, and Hx were quanti-
fied as described previously (31). Measurements were on DNA prepared 
from 3 animals per group, with the following exceptions: Aag+/+ untreated 
was 1 measurement from 2 pooled samples, Aag–/– untreated was from 2 
samples, and Aag+/+ at 7 days was from 2 samples for εA, εC, and 8oxoG, 
and only one for Hx.
Statistics
GraphPad Prism software was used for statistical analyses. Mann-Whitney 
test was used to compare tumor multiplicities and pathological scoring 
data. Fisher’s exact was used to compare frequencies. For H. pylori stud-
ies, group means of serum antibody titers and log-transformed bacterial 
colonization data were compared using a student’s t test. For DNA lesions, 
2-way ANOVA was used to assess effects of treatment and genotype. All 
P values listed are 2 sided except in our comparison of tumor incidence 
after 7 cycles of DSS where we were confirming that Aag deficiency 
increased tumor sensitivity. Data are mean ± SD.
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